Cantor Fitzgerald Reiterates Neutral on Merck & Co, Maintains $120 Price Target
Merck & Co., Inc.
Merck & Co., Inc. MRK | 0.00 |
Cantor Fitzgerald analyst Carter Gould reiterates Merck & Co (NYSE:
MRK) with a Neutral and maintains $120 price target.
